Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-14

FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for bupropion hydrochloride from Rising Pharma Holdings, Inc., authorizing the generic product's approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bupropion hydrochloride (Bupropion hydrochloride)

Snippet

SUPPL AP for BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE)